Related Experiment Video

Updated: Mar 11, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K

Relationship between selected DNA polymorphisms and coronary artery disease complications

Marcin Wirtwein1, Olle Melander2, Marketa Sjőgren2

  • 1Department of Pharmacology, Medical University of Gdansk, Debowa 23, 80-211 Gdansk, Poland.

International Journal of Cardiology
|November 27, 2016
PubMed

Insights

Certain single nucleotide polymorphisms (SNPs) in CXCL12, LDLR, and MRAS genes are linked to increased cardiovascular complications, including Major Advanced Cardiovascular Events (MACE) and revascularization, in coronary artery disease (CAD) patients.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Genomics

Background:

  • Coronary heart disease (CHD) arises from complex genetic and lifestyle factors.
  • Identifying genetic predispositions is crucial for understanding cardiovascular disease (CVD) risk.
  • Genetic risk factors for coronary artery disease (CAD) require further elucidation.

Purpose of the Study:

  • To investigate the association between specific single nucleotide polymorphisms (SNPs) and the risk of cardiovascular complications in patients with angiographically confirmed CAD.
  • To evaluate the predictive value of a multi-locus genetic risk score (GRS19) for adverse cardiovascular outcomes.

Main Methods:

  • A cohort of 1345 patients with CHD was followed for a median of 8.6 years.
  • Nineteen single nucleotide polymorphisms (SNPs) were analyzed for associations with Major Advanced Cardiovascular Events (MACE), Acute Coronary Syndromes (ACS), and revascularization.
  • A genetic risk score (GRS19) was constructed from the 19 investigated SNPs.

Main Results:

  • SNPs rs1746048 (CXCL12), rs9818870 (MRAS), and rs17114036 (PPAP2B) were associated with a higher risk of MACE.
  • SNPs rs1746048 (CXCL12) and rs1122608 (LDLR) were associated with an increased risk of revascularization.
  • The top quartile of GRS19 showed a significant association with combined endpoints, MACE, ACS, and revascularization.

Conclusions:

  • Specific SNPs in CXCL12 and LDLR are linked to revascularization risk.
  • CXCL12, LPA, MRAS, and PPAP2B SNPs are associated with MACE risk.
  • GRS19 effectively predicts cardiovascular complications in CAD patients with the highest genetic risk.
Abstract

Keywords:
Coronary artery diseaseDNA polymorphismsHypertension

More Related Videos

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format05:58

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Published on: August 20, 2018

11.5K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
81
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
69
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
19.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.3K